welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Coxib-inhibition of Duodenal Polyp Growth in FAP
study id #: NCT00844727
condition: Duodenal Polyposis
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.
start date: September 2003
estimated completion: April 2004
last updated: July 6, 2011
phase of development: Phase 2, Phase 3
size / enrollment: 38
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- FAP patient with previous colectomy and confirmed polyposis
- NSAID hypersensitivity
expertly curated content related to this topic
Functional Outcome After Colectomy and Ileorectal Anastomosis Compared with Proctocolectomy and Ileal Pouch-Anal Ana...OBJECTIVE : To compare the long-term fun...
This perspective discusses the clinical ...
Therapeutic Approaches for Patients with Coexisting Familial Adenomatous Polyposis and Colorectal CancerColorectal cancer is a major cause of de...
Gardner syndrome is a variant of familia...
A Randomised, Double Blind, Placebo Controlled Study of Celecoxib, a Selective Cyclooxygenase 2 Inhibitor, on Duoden...BACKGROUND : Non-selective cyclooxygenas...